{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:52:58Z","timestamp":1790833978562,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Treated AML patients often have measurable residual disease (MRD) due to persisting low-level clones. This study assessed whether residual post-treatment somatic mutations, detected by NGS, were significantly prognostic for subsequent clinical outcomes. AML patients (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009128) underwent both pre-and post-treatment testing with the same 42-gene MRD-validated NGS assay. After induction, 59 (46%) patients were mutation-negative (0.0024 VAF detection limit) and 69 (54%) had \u22651 persisting NGS-detectable mutation. Compared with NGS-negative patients, NGS-positive patients had shorter overall survival (17 months versus median not reached;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.004; hazard ratio\u2009=\u20092.2 [95% CI: 1.3\u20133.7]) and a shorter time to relapse (14 months versus median not reached;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.014; HR\u2009=\u20091.9 [95% CI: 1.1\u20133.1]). Among 95 patients with a complete morphologic remission (CR), 43 (45%) were MRD-positive by NGS and 52 (55%) were MRD-negative. These MRD-positive CR patients had a shorter overall survival (16.8 months versus median not reached;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.013; HR\u2009=\u20092.1 [95% CI: 1.2\u20133.9]) than did the MRD-negative CR patients. Post-treatment persisting MRD positivity, defined by the same NGS-based test used at diagnosis, is thus a more sensitive biomarker for low-level leukemic clones compared to traditional non-molecular methods and is prognostic of subsequent relapse and death.\n                  <\/jats:p>","DOI":"10.1038\/s41408-023-00833-7","type":"journal-article","created":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T23:10:44Z","timestamp":1682291444000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7326-0717","authenticated-orcid":false,"given":"Yonghong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9867-6265","authenticated-orcid":false,"given":"Jose","family":"Solis-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9010-8167","authenticated-orcid":false,"given":"Nicola","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen H.","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas L.","family":"Lacbawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick K.","family":"Racke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2103-5144","authenticated-orcid":false,"given":"Richard D.","family":"Press","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"833_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"833_CR2","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:2753\u201367.","journal-title":"Blood"},{"key":"833_CR3","unstructured":"Acute Myeloid Leukemia, Version 2.2022. NCCN Clinical Practice Guidelines in Oncology https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml_blocks.pdf Accessed 29 August 2022."},{"key":"833_CR4","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","volume":"6","author":"NJ Short","year":"2020","unstructured":"Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, et al. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: A systematic review and meta-analysis. JAMA Oncol. 2020;6:1890\u201399.","journal-title":"JAMA Oncol"},{"key":"833_CR5","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.5858\/arpa.2014-0543-CP","volume":"139","author":"M Keeney","year":"2015","unstructured":"Keeney M, Halley JG, Rhoads DD, Ansari MQ, Kussick SJ, Karlon WJ, et al. Marked variability in reported minimal residual disease lower level of detection of 4 hematolymphoid neoplasms: a survey of participants in the College of American Pathologists flow cytometry proficiency testing program. Arch Pathol Lab Med. 2015;139:1276\u201380.","journal-title":"Arch Pathol Lab Med"},{"key":"833_CR6","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"833_CR7","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022;40:850\u201364.e9.","journal-title":"Cancer Cell"},{"key":"833_CR8","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/ajh.25514","volume":"94","author":"RD Press","year":"2019","unstructured":"Press RD, Eickelberg G, Froman A, Yang F, Stentz A, Flatley EM, et al. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse. Am J Hematol. 2019;94:902\u201312.","journal-title":"Am J Hematol"},{"key":"833_CR9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/ajcp\/aqw016","volume":"145","author":"E Reinig","year":"2016","unstructured":"Reinig E, Yang F, Traer E, Arora R, Brown S, Rattray R, et al. Targeted next-generation sequencing in myelodysplastic syndrome and chronic myelomonocytic leukemia aids diagnosis in challenging cases and identifies frequent spliceosome mutations in transformed acute myeloid leukemia. Am J Clin Pathol. 2016;145:497\u2013506.","journal-title":"Am J Clin Pathol"},{"key":"833_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19:4\u201323.","journal-title":"J Mol Diagn"},{"key":"833_CR11","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"833_CR12","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-020-1089-8","volume":"26","author":"A Burd","year":"2020","unstructured":"Burd A, Levine RL, Ruppert AS, Mims AS, Borate U, Stein EM, et al. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med. 2020;26:1852\u201358.","journal-title":"Nat Med"},{"key":"833_CR13","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"833_CR14","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","volume":"378","author":"M Jongen-Lavrencic","year":"2018","unstructured":"Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378:1189\u201399.","journal-title":"N Engl J Med"},{"key":"833_CR15","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S, Bene MC, Buccisano F, Cloos J, et al. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131:1275\u201391.","journal-title":"Blood"},{"key":"833_CR16","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1200\/JCO.2017.77.6757","volume":"36","author":"K Morita","year":"2018","unstructured":"Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, et al. Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia. J Clin Oncol. 2018;36:1788\u201397.","journal-title":"J Clin Oncol"},{"key":"833_CR17","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","volume":"132","author":"F Thol","year":"2018","unstructured":"Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, et al. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood. 2018;132:1703\u201313.","journal-title":"Blood"},{"key":"833_CR18","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1182\/bloodadvances.2021004367","volume":"5","author":"M Heuser","year":"2021","unstructured":"Heuser M, Heida B, Buttner K, Wienecke CP, Teich K, Funke C, et al. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. Blood Adv. 2021;5:2294\u2013304.","journal-title":"Blood Adv"},{"key":"833_CR19","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.3324\/haematol.2020.263806","volume":"106","author":"C Sargas","year":"2021","unstructured":"Sargas C, Ayala R, Chillon MC, Larrayoz MJ, Carrillo-Cruz E, Bilbao C, et al. Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project. Haematologica. 2021;106:3079\u201389.","journal-title":"Haematologica"},{"key":"833_CR20","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1073\/pnas.1324297111","volume":"111","author":"MR Corces-Zimmerman","year":"2014","unstructured":"Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA. 2014;111:2548\u201353.","journal-title":"Proc Natl Acad Sci USA"},{"key":"833_CR21","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1200\/JCO.19.03011","volume":"38","author":"CS Hourigan","year":"2020","unstructured":"Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;38:1273\u201383.","journal-title":"J Clin Oncol"},{"key":"833_CR22","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562:526\u201331.","journal-title":"Nature"},{"key":"833_CR23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"833_CR24","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135:2137\u201345.","journal-title":"Blood"},{"key":"833_CR25","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1182\/bloodadvances.2020003717","volume":"5","author":"A Maiti","year":"2021","unstructured":"Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, et al. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv. 2021;5:1876\u201383.","journal-title":"Blood Adv"},{"key":"833_CR26","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1200\/JCO.21.01546","volume":"40","author":"KW Pratz","year":"2022","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Recher C, Schuh AC, Thirman MJ, et al. Measurable residual disease response and prognosis in treatment-naive acute myeloid leukemia with venetoclax and azacitidine. J Clin Oncol. 2022;40:855\u201365.","journal-title":"J Clin Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00833-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00833-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00833-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T23:11:24Z","timestamp":1682291484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00833-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["833"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00833-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2386724\/v1","asserted-by":"object"}]},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]},"assertion":[{"value":"16 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"YL, CHT, FLL, and FKR were employed by Quest Diagnostics during the study. Other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}